176 related articles for article (PubMed ID: 38635315)
21. Cervical cancer elimination in Italy: Current scenario and future endeavors for a value based prevention.
Calabrò GE; Riccardi MT; D'Ambrosio F; Castagna C; Sapienza M; Millevolte R; Pellacchia A; Ricciardi R; de Vincenzo RP; de Waure C
Front Public Health; 2022; 10():1010237. PubMed ID: 36530690
[TBL] [Abstract][Full Text] [Related]
22. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
[TBL] [Abstract][Full Text] [Related]
23. Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination.
Grimes DR; Corry EMA; Malagón T; O'Riain C; Franco EL; Brennan DJ
JAMA Netw Open; 2021 Jun; 4(6):e2115321. PubMed ID: 34190993
[TBL] [Abstract][Full Text] [Related]
24. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
[TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
26. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
27. Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination.
Pimenta JM; Galindo C; Jenkins D; Taylor SM
BMC Cancer; 2013 Nov; 13():553. PubMed ID: 24261839
[TBL] [Abstract][Full Text] [Related]
28. Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia.
Setiawan D; Dolk FC; Suwantika AA; Westra TA; WIlschut JC; Postma MJ
Value Health Reg Issues; 2016 May; 9():84-92. PubMed ID: 27881267
[TBL] [Abstract][Full Text] [Related]
29. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness of cytology and HPV-based screening strategy in cervical cancer screening: A cross-sectional population-based study in Chengdu, China.
Yao B; Peng J; Song W; Yang L; Zhang M; Wu X; Wu S; Wang X; Li C; Yang C
PLoS One; 2024; 19(2):e0299651. PubMed ID: 38422039
[TBL] [Abstract][Full Text] [Related]
31. Impact of human papillomavirus age-related prevalence and vaccination levels on interpretation of cervical screening modalities: a modelling study.
Grimes DR
BMJ Open; 2024 Feb; 14(2):e078551. PubMed ID: 38309749
[TBL] [Abstract][Full Text] [Related]
32. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
33. Estimating the long-term clinical impact of cervical cancer vaccination in Taiwan.
Yen MS; You SL; Ferko N; Debicki D; Chen YC; Chou CY
Int J Gynecol Cancer; 2009 Feb; 19(2):281-8. PubMed ID: 19396010
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.
Liu PH; Hu FC; Lee PI; Chow SN; Huang CW; Wang JD
BMC Health Serv Res; 2010 Jan; 10():11. PubMed ID: 20064239
[TBL] [Abstract][Full Text] [Related]
37. Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand.
Smith MA; Hall M; Lew JB; Canfell K
Vaccine; 2018 Oct; 36(42):6314-6324. PubMed ID: 30224201
[TBL] [Abstract][Full Text] [Related]
38. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
39. MOnitoring human papillomavirus Vaccine effect on Infection and cErvical diseases (MOVIE): Protocol for a cohort study using electronic health records from Yinzhou, China.
Deng S; Welby S; Liu Z; Yang Y; Meng R; Sun Y; Yang J; Liu G; He Y; Jiang N; Wu Z; Liu K; Rosillon D; Cohet C; Borys D; Zhan S
Hum Vaccin Immunother; 2023 Aug; 19(2):2257989. PubMed ID: 37813849
[TBL] [Abstract][Full Text] [Related]
40. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.
Demarteau N; Breuer T; Standaert B
Pharmacoeconomics; 2012 Apr; 30(4):337-53. PubMed ID: 22409292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
